Dear Clients,
Tradeo ceased offering trading services last year in May. Trading and ancillary will not recommence, and the brand/platform will be permanently discontinued.

For the clients with remaining balances, kindly send a withdrawal request through your login or via chat or email. If there are any queries or concerns relating to your account or any other matter, please email us at [email protected]


Johnson & Johnson Agrees to A $230 Million Opioid Drugs Settlement

Johnson & Johnson Agrees to A $230 Million Opioid Drugs Settlement

Johnson & Johnson agrees to pay out a $230 million settlement for its role in the opioid crisis in the US. Along with the settlement, J&J has reportedly agreed to stop selling opioids in the US.

This settlement may be the first of many that will follow as trials proceed nationwide. However, one of the conditions of the settlement is that Johnson & Johnson is excluded from the upcoming jury trial which begins today in New York. The lawsuit is charging multiple drug makers and distributors for deceptive marketing and downplaying the threat of the severely addictive drugs.

The Upcoming Lawsuit

New York Attorney General, Letitia James, has filed the US’ most comprehensive lawsuit against opioid manufacturers and distributors yet. The press release names these as the defendants in the trial: Purdue Pharma and its affiliates, members of the Sackler Family and trusts they control, Janssen Pharmaceuticals and its affiliates (including its parent company Johnson & Johnson), Mallinckrodt LLC and its affiliates, Endo Health Solutions and its affiliates, Teva Pharmaceuticals USA, Inc. and its affiliates, and Allergan Finance, LLC and its affiliates. The distributors named in the complaint are McKesson Corporation, Cardinal Health Inc., Amerisource Bergen Drug Corporation, and Rochester Drug Cooperative Inc. 

AG James argues that these companies have all contributed greatly to the opioid epidemic that has caused “widespread addiction, overdose, deaths, and suffering.” By using deceptive marketing and downplaying the severity of addiction to these substances, these companies have created the opioid crisis.

Attorney General James added, “We found that pharmaceutical manufacturers and distributors engaged in years of deceptive marketing about the risks of opioids and failed to exercise their basic duty to report suspicious behavior, leading to the crisis we are living with today. As the Sackler Family and the other defendants grew richer, New Yorkers’ health grew poorer and our state was left to foot the bill. The manufacturers and distributors of opioids are to blame for this crisis and it is past time they take responsibility.”

For Johnson & Johnson, a $230 million settlement is nothing more than a slap on the wrist, especially since the company wasn’t forced to admit liability in the settlement. However, going through a full trial is sure to be a very expensive venture, even for Johnson & Johnson. The company claims that they have decided to discontinue all its prescription pain meds in America this year. They may have gotten away with it this trial, but the road to forgiveness is yet long. According to the press release issued by the Office of the Attorney General of New York, over 130 people die of opioid-related overdoses daily in the US.

Legal disclaimer: The material does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instruments. UR Trade Fix Ltd accepts no responsibility for any use that may be made of these comments and for any consequences resulting in it. No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. The analysis does not involve any specific investment objectives, financial situation and needs of any specific person who may receive it. Past performance does not constitute a reliable indicator of future results and future forecasts do not constitute a reliable indicator of future performance.

It has not been prepared in accordance with legal requirements designed to promote the independence of research, and as such it is considered to be marketing communication. Although we are not specifically constrained from dealing ahead of the publication of our research, we do not seek to take advantage of it before we provide it to our clients. We aim to establish, maintain and operate effective organizational and administrative arrangements with a view to taking all reasonable steps to prevent conflicts of interest from constituting or giving rise to a material risk of damage to the interests of our clients. We operate a policy of independence, which requires our employees to act in our clients’ best interests when providing our services.